FY2026 Q1 Financial Results Presentation

from the beginning

FY2026 Q1 Financial Results Presentation

Forward-Looking Statements

1 FY2025 Correction of Financial Results

Correction of the Consolidated Financial Results for FY2025, Submitted to the Tokyo Stock Exchange on July 31, 2026

5-Year Business Plan (FY2021-FY2025) Recap: Financial Targets (Updated)

2 FY2026 Q1 Financial Results

Summary

Overview of FY2026 Q1 Results

Revenue

Operating Profit

Profit Attributable to Owners of the Company

3 FY2026 Forecast

Revision of FY2026 Forecast

4 Business Update

Performance

Performance

5 R&D Update

Growth of DXd ADC during 5YBP (FY2026-FY2030) and Identification of Breakthrough Generating Technology (BGT)

Indication Expansion to HER2+ Early Breast Cancer in the Curative-Intent Setting

Regulatory Updates

New Indication Approval for 1L metastatic TNBC in US

Targeting Unmet Needs in Muscle-Invasive Urothelial Carcinoma with combination therapy

Novel Regulatory T (Treg) Cell-Directed ADC

Regulatory Updates

FY2026 News Flow

Q&A

• Q&A 1

13

Q&A 1

• Q&A 2

4

• Q&A 3

13

• Q&A 4

13

Q&A 4

• Q&A 5

25

• Q&A 6

13

10

• Q&A 7

23

23